Status:
COMPLETED
A Study to Assess the Drug Interaction Between MYK-224 and Itraconazole and Verapamil in Healthy Participants
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Healthy Participants
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the effect of co-administration of itraconazole or verapamil on the drug levels of MYK-224 in healthy participants.
Eligibility Criteria
Inclusion
- Body mass index between 18 and 30 kg/m\^2, inclusive
- Healthy as determined by medical history, physical examination, vital signs, 12-lead electrocardiogram and routine laboratory assessments
- Adequate acoustic windows to enable accurate transthoracic echocardiographic assessment
- Left Ventricular Ejection Fraction (LVEF) ≥60% at screening and ≥55% prior to MYK-224 dosing
Exclusion
- Any acute or chronic medical illness
- History of dizziness and/or recurrent headaches
- History of heart disease
- Other protocol-defined inclusion/exclusion criteria apply
Key Trial Info
Start Date :
April 21 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 29 2022
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT05304533
Start Date
April 21 2022
End Date
November 29 2022
Last Update
January 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution - 0001
Dallas, Texas, United States, 75247